Vancouver, British Columbia, Canada – 23. January 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (badger „Companies“) is pleased to announce that its wholly owned subsidiary Vocan Biotechnologies Inc. („calling“) a investment assembled hat, the required is over with the Procedure to begin the recombinant production of psilocybin. The procedure, in which bacteria are equipped with optimized biosynthetic genes from the fungus Psilocybe cubensis, will enable the bacteria to act as a kind of biological factory and inexpensively synthesize psilocybin with simple building blocks.
The platform by Vocan can produce the active compounds that occur naturally through a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds as well as known and new analogs.
The analog connections could prove to be more effective, targeted and safer.
Vocan now has the required investment received and assembled to carry out his plan to make biosynthetic psilocybin. Because of the cost and long lead time, this is a critical milestone in the company’s plan.
The facility will allow Vocan to improve on the work currently under way in the laboratory and bring Vocan one step closer to the timeline to begin recombinant psilocybin production.
The amount of psilocybin needed on just a few days, compared to the lot expenditureOuter and more expensive methods of extraction from whole mushrooms. With the purchase and installation of the system, Vocan is able to achieve its goals in the short term“said the company’s CEO, Joel Shacker.
In connection with the company’s press release dated January 15, 2021 announcing the completion of the sale of non-core assets, the company wishes to correct that it has issued a total of 500,000 shares of common stock as an administration fee to three independent third parties involved in handling this sale have assisted, and not 350,000 shares to two parties as previously announced.
over Core One Labs Inc.
Core One Labs Inc. is a biotechnological one Research and DevelopmentCompany focused on life sciences and bringing psychedelic drugs to market through novel delivery systems and psychedelic assisted psychotherapy.
The company has developed a patent-pending, thin, oral film strip (the “Technology”) that instantly dissolves when placed in the mouth and releases organic molecules into the bloodstream in precise amounts while maintaining excellent bioavailability. With this technology, the company intends to his IPAdvancing technology to focus on delivering psychedelic molecules, with the Focus on first biosynthetisiertem Psilocybin lies. Core One also has a stake in outpatient departments, which together maintain a database of over 200,000 patients. Through research and development in these outpatient departments, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the company intends to work on regulatory approval for research that advances psychedelic-based treatments for mental illness.
Core One Labs Inc.
Chief Executive Officer
For more information, please contact:
Precautionary note / disclaimer:
The Canadian Securities Exchange (CSE) has not reviewed this release and assumes no responsibility for the adequacy or accuracy of the contents of this news release.
The company advises that all forward-looking statements are fundamentally uncertain and that actual performance can be influenced by a number of important factors over which the company has no influence. Such factors include, but are not limited to, risks and uncertainties related to the company’s relatively short life and the need to comply with environmental and regulatory requirements. As a result, actual and future events, conditions and results could differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information.
The company has no obligation to correct forward-looking information unless required by applicable securities laws. Additionally, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to use substances under the Controlled Drugs and Substances Act (Canada) to own without a prescription. Health Canada has not approved psilocybin as a drug for any indication. Core One Labs Inc. is not directly or indirectly involved in the illegal sale, manufacture or distribution of psychedelic substances in the countries in which it operates. Core One While Labs Inc. believes that psychedelic substances can be used to treat certain medical conditions, it does not advocate legalizing psychedelic substances for recreational use. Core One Labs Inc. does not deal in psychedelic substances unless they are used in laboratory tests and clinical studies within an approved regulatory framework.
The German version can be shortened or summarized. No responsibility or liability is assumed for the content, correctness, appropriateness or accuracy of this translation. From the perspective of the translator, the message does not constitute a buy or sell recommendation! Please note the original English message on www.sedar.com, www.sec.gov, www.asx.com.au/ or on the company website!
Stocks on the radar:UBM, FACC, Warimpex, Rosenbauer, Frequentis, Agrana, Austrian post, Palfinger, Wienerberger, Andritz, Bawag, Rather S, Porn, Rosgix, Uniqa, DO&CO, Gurktaler AG strain, Gurktaler AG VZ, SBO, Viennese private bank, RHI Magnesita, Cleen Energy, BKS bank trunk, SW environmental technology, Linz Textil Holding, Success AG, Pierer Mobility AG, BTV AG, Marinomed Biotech, LINDE.
[ source link ]
Core Labs announces Vocan building facility produce biosynthesized psilocybin